Kisilea

Icatibant, the active ingredient in Kisilea, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL injectable solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1 inhibitor deficiency.

GNH USA supplies Kisilea as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage hereditary angioedema, a disorder of the bradykinin pathway.

- Hereditary angioedema type I: rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: rapid reduction of swelling during acute attacks. - Hereditary angioedema with normal C1‑inhibitor: relief of acute swelling episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain or erythema. - Headache. - Nausea. - Fatigue. - Dizziness. - Flushing.

Serious or Rare Side Effects: - Hypersensitivity reactions including anaphylaxis. - Severe hypotension. - Angioedema unrelated to HAE. - Thrombocytopenia. - Cardiac arrhythmias. - Severe injection site infection.

Before using Kisilea, consider the following safety measures.

- Contraindication: Do not use in patients with known hypersensitivity to icatibant or any excipients. - Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: Assess risk versus benefit, as icatibant may be excreted in milk. - Renal impairment: Monitor closely; no dosage adjustment is established. - Immunocompromised patients: Observe for signs of infection at the injection site. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines; consider the following.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, potentially enhancing adverse effects. - Angiotensin receptor blockers (ARBs): similar risk of elevated bradykinin.

Moderate Interactions (Monitor Closely): - Other bradykinin pathway modulators: monitor for additive effects. - Antihistamines: may mask early signs of hypersensitivity. - Diuretics: watch for blood pressure changes. - NSAIDs: may increase risk of renal impairment. - Concomitant subcutaneous injections at the same site: may increase local irritation.